Pharmaceutical

Neuvivo makes bid to enter ALS arena with immunotherapy candidate

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

Oct 8, 2024 - 04:00
Neuvivo makes bid to enter ALS arena with immunotherapy candidate
NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.
Read the original article

Tags:

Previous Article

A rational design approach to RNA targeting could replace large-scale screening

Next Article

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Esketamine tops quetiapine for treatment-resistant depression in head-to-head trial

Esketamine tops quetiapine for treatment-resistant depr...

Oct 4, 2023

SCOPE: Changing protocol language and site actions are key to making trials inclusive

SCOPE: Changing protocol language and site actions are ...

Feb 14, 2024

STAT+: Congress ditches site-neutral hospital pay policy

STAT+: Congress ditches site-neutral hospital pay policy

Feb 27, 2024